423 / 1631
Antibody
Target
Company
Nivolumab
PD1
BMS
Pembrolizumab
PD1
MSD
REGN2810
PD1
Regeneron
Durvalumab
PD-L1
Celgene, AstraZeneca
Avelumab
PD-L1
Pfizer
Ipilimumab
CTLA-4
BMS
Immunomodifiers in Lymphoma
Selection
|
|
423 / 1631
Antibody
Target
Company
Nivolumab
PD1
BMS
Pembrolizumab
PD1
MSD
REGN2810
PD1
Regeneron
Durvalumab
PD-L1
Celgene, AstraZeneca
Avelumab
PD-L1
Pfizer
Ipilimumab
CTLA-4
BMS
Immunomodifiers in Lymphoma
Selection